Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q96NX5

UPID:
KCC1G_HUMAN

ALTERNATIVE NAMES:
CaM kinase I gamma; CaMK-like CREB kinase III

ALTERNATIVE UPACC:
Q96NX5; Q86UH5; Q9Y3J7

BACKGROUND:
The protein known as Calcium/calmodulin-dependent protein kinase type 1G, with alternative names CaM kinase I gamma and CaMK-like CREB kinase III, is integral to calcium-triggered signaling pathways. It specifically phosphorylates the transcription factor CREB1, indicating its crucial role in modulating cellular responses to calcium signals.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Calcium/calmodulin-dependent protein kinase type 1G offers a promising avenue for the development of novel therapeutic approaches. By targeting the signaling pathways mediated by this kinase, new treatments for diseases with underlying disruptions in calcium signaling could be developed.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.